Dostarlimab Plus Chemotherapy Shows Similar HRQOL Results in Patients With Endometrial Cancer
June 4th 2023New patient reported outcomes from the phase 3 RUBY trial show patients with primary advanced or recurrent endometrial cancer maintained their health-related quality of life when on dostarlimab and chemotherapy.
Read More
BRCA-Mutated mCRPC Has Worse Outcomes Than Non-BRCA HRR Population
June 4th 2023When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.
Read More
Adjuvant Osimertinib Extends Survival in EGFR-Positive, Stage IB-IIIA NSCLC
June 4th 2023ADAURA is the first global phase 3 study to demonstrate statistically significant and clinically meaningful disease-free survival and overall survival benefit with adjuvant targeted therapy for patients with EGFR-mutated, stage IB to IIIA NSCLC.
Read More
STRIDE Regimen Exhibits Manageable Safety in Patients With uHCC
June 3rd 2023According to George Lau, MD, FRCP, FAASLD, patients with unresectable hepatocellular carcinoma who experienced immune-related adverse events with the STRIDE regimen were not precluded from receiving survival benefit.
Read More